<DOC>
	<DOCNO>NCT01043016</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose Photocyanine injection photodynamic therapy malignant tumor ( especially skin cancer esophageal cancer ) . Projected accrual : A total 18-24 patient accrue study .</brief_summary>
	<brief_title>Safety Study Photodynamic Therapy Using Photocyanine Injection Treating Patients With Malignant Tumors</brief_title>
	<detailed_description>Photocyanine injection type cyanine compound , invent Fuzhou university Professor Chen ; 's maximum absorption wave 670 nm . Patients receive intravenous injection Photocyanine injection , 24 hour later , patient undergo photodynamic therapy . Cohorts 3-6 patient receive escalate dos Photocyanine Injection photodynamic therapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 patient experience dose-limiting toxicity . Three additional patient treat MTD . After completion study therapy , patient follow 2 week .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Aged 18 70 year old ( patient 60 year old must three kind complication heart , lung , liver kidney function time ) , gender limit ; 2 . Advanced malignant solid tumor confirm histology cytology ( skin cancer esophageal cancer ) , malignant tumor illuminate directly ( via endoscopy ) laser fiber ; 3 . Recurrence surgery , radiotherapy , chemoradiotherapy ; financial difficulty , give treatment ; 4 . Patients receive chemotherapy , biological therapy research drug must exceed least 4 week five halflife ; 5 . Life expectancy : &gt; 3 month ; 6 . Can collaboratively observe adverse event efficacy ; 7 . No antitumor treatment ( include steroid ) ; 8 . Patients legal representative sign inform consent ; 9 . Performance status : ECOG ≤ 2 , 1 . No pathological evidence ; 2 . Have allergic effect drug ; 3 . HIV antibody positive , suffer acquire congenital immune deficiency disease , organ transplant history ; 4 . Neutrophil count &lt; 1.5 × 109 / L , platelet &lt; 100 × 109 / L , hemoglobin &lt; 90 g /L ; 5 . Serum Cr 1.5 time normal reference range Cr clearance rate &lt; 50 ml/min ; 6 . ALT , AST &gt; 2.5 time normal range hepatic metastasis occur ; ALT , AST &gt; 5 time normal range hepatic metastasis exist ; 7 . Serum bilirubin &gt; 1.5 time normal range ; 8 . Fever 38 ℃ , active infection affect clinical trial obviously ; 9 . Hypertension fail control ( systolic blood pressure &gt; 160 mmHg diastolic pressure &gt; 100 mmHg ) ; 10 . Obvious cardiovascular disorder ( eg , myocardial infarction , superior vena cava syndrome , two grade heart disease , heart disease increase risk ventricular arrhythm ) ; 11 . Not recover anticancer therapy surgery ; 12 . Any clinical problem beyond control ( severe mental , neurological , cardiovascular , respiratory system disease , etc . ) ; 13 . Evidence central nerve system metastasis ; 14 . Have gastrointestinal disease affect distribution , metabolism removal drug ; 15 . Pregnant breastfeeding woman ; 16 . Poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>skin cancer</keyword>
	<keyword>esophageal cancer</keyword>
	<keyword>photodynamic therapy</keyword>
</DOC>